Ikemoto, S., Takahashi, M., Tsunoda, N., Maruyama, K., Itakura, H., & Ezaki, O
The review traced the developmental history of GLP-1 research from the identification of the proglucagon gene in 1982 through to the contemporary landscape of GLP-1-based therapeutics across obesity, cardiovascular disease, NAFLD, neurodegeneration, and cancer biology
In the TRIUMPH-1 Phase 3 trial, participants experienced up to 28.3% weight loss over 80 weeks, demonstrating its potential effectiveness against other medications like tirzepatide
The most common side effects were: Nausea Vomiting Diarrhea Constipation Fatigue Abdominal discomfort Early satiety Injection site reactions Increased heart rate in the first 24 weeks, but that returned to normal after 24 weeks
Banking variety matters, but so does clarity
Around-the-clock support staffed by trained agents can resolve account questions, walk through bonus terms, and troubleshoot device-related issues